Modifiers of LRRK2 parkinsonism: new therapeutic targets

Owen A. Ross; Rosa Rademakers

doi:10.1016/S1474-4422(16)30243-5

Modifiers of LRRK2 parkinsonism: new therapeutic targets

Owen A. Ross, Rosa Rademakers

Neuroscience

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1200-1201
Number of pages	2
Journal	The Lancet Neurology
Volume	15
Issue number	12
DOIs	https://doi.org/10.1016/S1474-4422(16)30243-5
State	Published - Nov 1 2016

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(16)30243-5

Cite this

@article{036c2cc2d2e84bd89e75a16f814b41fb,

title = "Modifiers of LRRK2 parkinsonism: new therapeutic targets",

author = "Ross, {Owen A.} and Rosa Rademakers",

note = "Funding Information: We declare no competing interests. OAR is supported by NINDS R01 NS078086 and the Mayo Clinic Morris K Udall Parkinson's Disease Research Center of Excellence ( NINDS P50 #NS072187 ). RR is supported by NINDS R01 NS 080882, P50 NS72187 and R01-NS076471, NIA P50 AG016574 and the Consortium for Frontotemporal Dementia Research. ",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/S1474-4422(16)30243-5",

language = "English (US)",

volume = "15",

pages = "1200--1201",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "12",

}

TY - JOUR

T1 - Modifiers of LRRK2 parkinsonism

T2 - new therapeutic targets

AU - Ross, Owen A.

AU - Rademakers, Rosa

N1 - Funding Information: We declare no competing interests. OAR is supported by NINDS R01 NS078086 and the Mayo Clinic Morris K Udall Parkinson's Disease Research Center of Excellence ( NINDS P50 #NS072187 ). RR is supported by NINDS R01 NS 080882, P50 NS72187 and R01-NS076471, NIA P50 AG016574 and the Consortium for Frontotemporal Dementia Research.

PY - 2016/11/1

Y1 - 2016/11/1

UR - http://www.scopus.com/inward/record.url?scp=84992187096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992187096&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(16)30243-5

DO - 10.1016/S1474-4422(16)30243-5

M3 - Comment/debate

C2 - 27692901

AN - SCOPUS:84992187096

SN - 1474-4422

VL - 15

SP - 1200

EP - 1201

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 12

ER -

Modifiers of LRRK2 parkinsonism: new therapeutic targets

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this